STOCK TITAN

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Phathom Pharmaceuticals to participate in investor conferences in November
Positive
  • Phathom Pharmaceuticals, Inc. will be participating in several investor conferences in November. The company's management team will be presenting at the Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology Conference, the Jefferies London Healthcare Conference, the Stifel 2023 Healthcare Conference, the Craig-Hallum 14th Annual Alpha Select Conference, and the Evercore ISI 6th Annual HealthCONx Conference. The company will also be holding one-on-one meetings throughout these conferences. Investors can access live webcasts and archived recordings of each event on the Phathom website.
Negative
  • None.

FLORHAM PARK, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in November:

Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology Conference in New York, NY
Date: Tuesday, November 7, 2023
Live Webcast: 2:30 p.m. ET
Management to participate in one-on-one meetings throughout the conference

Jefferies London Healthcare Conference in London, England
Date: Tuesday, November 14, 2023
Live Webcast: 10:30 a.m. ET
Management to participate in one-on-one meetings throughout the conference

Stifel 2023 Healthcare Conference in New York, NY
Date: Wednesday, November 15, 2023
Live Webcast: 2:25 p.m. ET
Management to participate in one-on-one meetings throughout the conference

Craig-Hallum 14th Annual Alpha Select Conference in New York, NY
Date: Thursday, November 16, 2023
Management to participate in one-on-one meetings throughout the conference

Evercore ISI 6th Annual HealthCONx Conference in Miami, FL
Date: Wednesday, November 29, 2023
Live Webcast: 4:15 p.m. ET
Management to participate in one-on-one meetings throughout the conference

To access the live webcast and archived recordings of each event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. Recordings will be available for 90 days following the conclusion of each meeting.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and Twitter.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2023 Phathom Pharmaceuticals. All rights reserved.


FAQ

What conferences will Phathom Pharmaceuticals be participating in November?

Phathom Pharmaceuticals will be participating in the Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology Conference, the Jefferies London Healthcare Conference, the Stifel 2023 Healthcare Conference, the Craig-Hallum 14th Annual Alpha Select Conference, and the Evercore ISI 6th Annual HealthCONx Conference.

How can investors access the presentations and recordings of the conferences?

Investors can access the live webcast and archived recordings of each event on the News & Events section of the Phathom website.

Will Phathom Pharmaceuticals be holding one-on-one meetings during the conferences?

Yes, the company's management team will be participating in one-on-one meetings throughout the conferences.

Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

PHAT Rankings

PHAT Latest News

PHAT Stock Data

591.09M
42.90M
8.81%
87.86%
18.21%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
FLORHAM PARK

About PHAT

phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.